Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs

(2015) M. Boi et al.   CLINICAL CANCER RESEARCH

Abstract LB-231: A phase I pharmacokinetic study of OTX015 for the treatment of patients with hematologic malignancies

(2015) Elodie Odore et al.   CANCER RESEARCH

Abstract 5531: OTX015, a novel BET inhibitor, is a promising anticancer agent for multiple myeloma

(2015) Maria Todaro et al.   CANCER RESEARCH

Development and validation of an UPLC-MS/MS method for quantitative analysis of OTX015 in human plasma samples

(2014) Elodie Odore et al.   Analytical Methods

5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies

(2014) A. Stathis et al.   EUROPEAN JOURNAL OF CANCER

Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients

(2014) Quentin Chalret du Rieu et al.   INVESTIGATIONAL NEW DRUGS

Abstract C244: Development of the BET bromodomain inhibitor OTX015.

(2014) J. K. Noel et al.   MOLECULAR CANCER THERAPEUTICS

A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies

(2014) K Althoff et al.   ONCOGENE

Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer

(2013) T. Shimamura et al.   CLINICAL CANCER RESEARCH

Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma

(2013) Z. Cheng et al.   CLINICAL CANCER RESEARCH

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia

(2012) C. J. Ott et al.   BLOOD

Down-regulation of NF-κB Transcriptional Activity in HIV-associated Kidney Disease by BRD4 Inhibition

(2012) Guangtao Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting MYC dependence in cancer by inhibiting BET bromodomains

(2011) J. A. Mertz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE